OUR STORY
Novigenix helps bring intelligent insights into the heterogeneity of patient response to cancer and its treatment for development of better therapeutics. AI combined with access to large sets of patient clinical and RNA data allows us to analyse patients’ immune profiles, and gain insights that can provide precise information, develop predictive capabilities, and tailor development of new therapies based on patient´s immune response to cancer.
Artificial Intelligence (AI) brings new possibilities to impact cancer patient outcomes. Over the past decade the Novigenix team has developed core competencies in development and measurement of RNA molecular biomarkers that are indicators of the presence or severity of a disease, in development of state-of-the-art data analytical models, and in regulatory approval of IVD products.
Novigenix analyses large amounts of RNA data from different patients’ blood to generate precise information about the patient response to cancer, the evolution of the cancer, and response to treatment. Novigenix solutions employ cutting edge molecular technologies ranging from NGS to RT-PCR based platforms, and they leverage the company’s proprietary Immuno-Transcriptomics LITOSeek™ platform which has been optimized and standardized for integrating patient multi-omics data with advanced Machine Learning and artificial intelligence approaches to map the response of the immune system to onset and progression of disease.
WHO ARE WE
A pioneering team
We are a pioneering company made up of experienced, bold and dedicated individuals with a clear understanding of complex host immune response pathways and data-driven intelligent algorithms.
Democratizing solution providers
We provide new and actionable information on patient immune response to disease using expertise in immunology, molecular biology, bioinformatics, and machine learning to reveal, each day, more insights into the heterogeneity of host immune response for development of novel therapeutic modalities that can improve patient’s therapeutic journeys.
Enablers
We cooperate closely with biopharmaceutical companies and academic centers of excellence to leverage Immuno-Transcriptomics and improve our understanding of disease progression and response to therapy, integrating patient data and the host’s immune response to provide a holistic view of the tumor-host interaction.
IMMUNO-TRANSCRIPTOMIC (ITO) timeline
